share_log

HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

HeartSciences宣布在世界麻醉师大会上发表讲台,介绍MyoVista Wavelet ECG在术前患者左心舒张功能障碍检测中的实用性
GlobeNewswire ·  03/26 09:00

Data Demonstrated the Use of MyoVista wavECGTM for Screening Preoperative Patients for LVDD Can Be Recommended

数据表明,可以推荐使用MyoVista WaveCGTM对术前患者进行LVDD筛查

Southlake, Texas, March 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced the podium presentation of a study utilizing its MyoVista wavECG device at the 18th World Congress of Anesthesiologists in Singapore.

德克萨斯州绍斯莱克,2024 年 3 月 26 日(GLOBE NEWSWIRE)— 心脏测试实验室有限公司 d/b/a HeartSciences(纳斯达克股票代码:HSCS;HSCSW)(“HeartSciences” 或 “公司”)是一家由人工智能(AI)驱动的医疗技术公司,致力于改造心电图/心电图以通过尽早发现心脏病来挽救生命,今天宣布在讲台上介绍一项利用其MyoVista进行的研究 wav心电图设备位于 18第四 世界麻醉师大会 在新加坡。

Preoperative left ventricular diastolic dysfunction (LVDD) is very common and one of the important causes of perioperative morbidity and mortality in cardiac and non-cardiac surgeries. In the study, patients undergoing preoperative anesthesia evaluation for cardiac and non-cardiac surgeries were enrolled. For patients indicated for preoperative echocardiography, LVDD was diagnosed and graded as per American Society of Echocardiography (ASE) guidelines and a MyoVista wavECG was also performed.

术前左心舒张功能障碍(LVDD)非常常见,是心脏和非心脏手术围手术期发病率和死亡率的重要原因之一。在这项研究中,入组了接受心脏和非心脏手术术术前麻醉评估的患者。对于需要进行术前超声心动图检查的患者,根据美国超声心动图学会(ASE)指南和MyoVista对LVDD进行诊断和分级 wav还进行了心电图检查。

The author of the study stated in his presentation, "In our cohort of mixed surgical population, the MyoVista wavECG was useful as a screening tool with 100% sensitivity. Based on these findings, 25 of the 60 non-LVDD patients could be safely excluded from referral to preoperative echocardiography. Also, MyoVista wavECG can raise red flag for more detailed examination by expert cardiologists when findings are positive." The author concluded, "The use of MyoVista wavECG for screening preoperative patients for LVDD to reduce the burden of referrals to preoperative echocardiography may be feasible and should be investigated further."

该研究的作者在演讲中指出:“在我们的混合手术人群中,MyoVista wav心电图可用作灵敏度为100%的筛查工具。根据这些发现,在60名非LVDD患者中,有25名可以安全地排除在术前超声心动图转诊范围之外。另外,myoVista wav当发现阳性时,心电图可能会引发危险信号,让专业心脏病专家进行更详细的检查。”作者得出结论:“MyoVista的使用 wav对术前患者进行LVDD筛查以减轻术前超声心动图转诊的负担的心电图可能是可行的,应进一步研究。”

"Once again, MyoVista wavECG has demonstrated significant potential value for screening in a large, at-risk patient population. The presentation of this study using the MyoVista to the World Congress of Anesthesiologists comes on the back of a recent publication assessing the use of MyoVista for identifying heart disease in diabetic patients1, which demonstrated MyoVista significantly outperformed existing standards of care," said Andrew Simpson, Chief Executive Officer of HeartSciences. "AI-ECG and MyoVista provide the opportunity to screen for heart disease and transform cardiovascular medicine. We look forward to making the MyoVista device commercially available in the short term and also bringing to market a range of AI-ECG algorithms via a hardware agnostic platform. In combination, this will allow HeartSciences to provide AI-ECG solutions in any care environment worldwide."

“再一次,MyoVista wav心电图已显示出在大量高危患者群体中进行筛查的巨大潜在价值。这项使用MyoVista向世界麻醉师大会介绍的研究是在最近发表的一篇文章的背景下发布的,该出版物评估了使用MyoVista识别糖尿病患者心脏病的情况。1,这表明MyoVista的表现明显优于现有的护理标准。” HeartSciences首席执行官安德鲁·辛普森说。“AI-ECG和MyoVista为筛查心脏病和改变心血管医学提供了机会。我们期待在短期内将MyoVista设备上市,并通过与硬件无关的平台将一系列AI-ECG算法推向市场。综上所述,这将使HeartSciences能够在全球任何护理环境中提供人工智能心电图解决方案。”


1 - Use of the energy waveform electrocardiogram to detect subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus Cheng Hwee Soh1,2, Alex G. C. de Sá2,3,4,5, Elizabeth Potter1, Amera Halabi1, David B. Ascher2,3,4,5 and Thomas H. Marwick1,2,6*


1-使用能量波形心电图检测 2 型糖尿病患者的亚临床左心功能障碍 Cheng Hwee Soh1,2、Alex G.C. de Sa'2,3,4,5、Elizabeth Potter1、Amera Halabi1、David B. Ascher2,4,5 和 Thomas H. Marwick1,2,6*

About HeartSciences

关于《心脏科学》

Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and intends to provide these AI-ECG algorithms on a device agnostic cloud-based solution as well as a low-cost ECG hardware platform. Working with clinical experts, HeartSciences ensures that all solutions are designed to work within existing clinical care pathways, making it easier for clinicians to use AI-ECG technology to improve their patient's care and lead to better outcomes. HeartSciences' first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test.

Heart Test Laboratories, Inc. d/b/a HeartSciences是一家医疗技术公司,专注于将基于人工智能的创新技术应用于心电图(也称为心电图),以扩大和改善心电图的临床用途。每周进行数百万次心电图检查,该公司的目标是通过使其成为更有价值的心脏筛查工具来改善医疗保健,尤其是在一线或即时临床环境中。HeartSciences拥有最大的AI-ECG算法库之一,并打算在与设备无关的基于云的解决方案以及低成本的心电图硬件平台上提供这些AI-ECG算法。HeartSciences与临床专家合作,确保所有解决方案的设计都符合现有的临床护理途径,从而使临床医生更容易使用AI-ECG技术来改善患者的护理并带来更好的疗效。HeartSciences 首款获得 FDA 批准的候选产品 MyoVista wavECG(简称 MyoVista)是一种静息的 12 导联心电图,也旨在提供与心脏功能障碍相关的诊断信息,而这些信息传统上只能通过心脏成像获得。在同一测试中,MyoVista还提供传统的心电图信息。

For more information, please visit: . X: @HeartSciences

欲了解更多信息,请访问: 。X: @HeartSciences

Safe Harbor Statement

安全港声明

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' Annual Report on Form 10-K for the fiscal year ended April 30, 2023, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 18, 2023, HeartSciences' Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2023, filed with the SEC on September 14, 2023, HeartSciences' Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2024, filed with the SEC on March 14, 2024, and in HeartSciences' other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

本公告包含经修订的1933年《证券法》第27A条和经修订的1934年《证券交易法》第21E条所指的前瞻性陈述。这些前瞻性陈述是根据1995年《私人证券诉讼改革法》的 “安全港” 条款作出的,与公司未来的财务和经营业绩有关。除历史事实陈述外,此处包含的所有陈述均为 “前瞻性陈述”,除其他外,包括有关HeartSciences信念和期望的陈述。这些陈述基于当前的预期、假设和不确定性,涉及对未来经济、竞争和市场状况以及未来业务决策等的判断,所有这些都很难或不可能准确预测,其中许多是公司无法控制的。这些前瞻性陈述中反映的预期涉及重要的假设、风险和不确定性,这些预期可能被证明是不正确的。投资者不应过分依赖这些前瞻性陈述,这些陈述仅代表截至本新闻稿发布之日。潜在风险和不确定性包括但不限于HeartSciences于2023年7月18日向美国证券交易委员会(“SEC”)提交的截至2023年4月30日财年的10-K表年度报告、HeartSciences于2023年9月14日向美国证券交易委员会提交的截至2023年7月31日财季10-Q表季度报告中所讨论的风险截至2024年1月31日的财季问题,于2024年3月14日向美国证券交易委员会提交,在HeartSciences向美国证券交易委员会提交的其他文件中www.sec.gov。除证券法要求外,公司不承担更新这些前瞻性陈述的责任。

Contacts:

联系人:

HeartSciences
Gene Gephart
+1-682-244-2578 (US)
info@heartsciences.com

心脏科学
Gene Gephart
+1-682-244-2578(美国)
info@heartsciences.com

Investors
Gilmartin Group
Vivian Cervantes
investorrelations@heartsciences.com

投资者
吉尔马丁集团
薇薇安·塞万提斯
investorrelations@heartsciences.com


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发